
The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three years of slow uptake for a medicine once viewed as a future blockbuster.

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three years of slow uptake for a medicine once viewed as a future blockbuster.